<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310021</url>
  </required_header>
  <id_info>
    <org_study_id>16-508</org_study_id>
    <nct_id>NCT03310021</nct_id>
  </id_info>
  <brief_title>A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;This is a single-center, randomized, double-blind, and placebo-controlled trial designed to:&#xD;
      1) demonstrate the degree to which administered andexanet doses can reverse Factor Ten A&#xD;
      (FXa)-inhibitor induced anticoagulation; and 2) evaluate the safety and PK/PD of andexanet in&#xD;
      healthy Japanese subjects taking direct FXa inhibitors at therapeutic doses.&quot;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">August 13, 2019</completion_date>
  <primary_completion_date type="Actual">August 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blind (Participant, Care Provider, Investigator, Sponsor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir.</measure>
    <time_frame>Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours</time_frame>
    <description>The primary efficacy endpoint is the percent change in the anti-FXa activity from baseline to the end of infusion (EOI) nadir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Anti-Fxa Activity From Baseline to the End of Bolus (EOB) Nadir.</measure>
    <time_frame>Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours</time_frame>
    <description>The percent change from baseline in anti-FXa activity at its end of bolus (EOB) nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Bolus (EOB) Nadir.</measure>
    <time_frame>Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours</time_frame>
    <description>The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOB nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Infusion (EOI) Nadir.</measure>
    <time_frame>Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours</time_frame>
    <description>The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOI nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thrombin Generation From Baseline to the End of Bolus (EOB) Nadir.</measure>
    <time_frame>Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours</time_frame>
    <description>The change in thrombin generation from baseline to its EOB peak.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thrombin Generation From Baseline to the End of Infusion (EOI) Nadir.</measure>
    <time_frame>Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours</time_frame>
    <description>The change in thrombin generation from baseline to its EOI peak.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban + low dose andexanet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban + high dose andexanet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edoxaban + high dose andexanet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edoxaban + high dose andexanet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban + low dose andexanet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban + high dose andexanet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edoxaban + low dose andexanet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban + low dose andexanet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban + low dose andexanet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edoxaban + low dose andexanet</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Andexanet alfa</intervention_name>
    <description>fXa inhibitor antidote</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
    <other_name>200 mg/vial for IV injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>factor Xa inhibitor</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>factor Xa inhibitor</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>factor Xa inhibitor</description>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <other_name>Savaysa, Lixiana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be in reasonably good health as determined by the Investigator based on medical&#xD;
             history, full physical examination (including blood pressure and pulse rate&#xD;
             measurement), 12-lead ECG, and clinical laboratory tests. Subjects with&#xD;
             well-controlled, chronic, stable conditions (e.g., controlled hypertension,&#xD;
             non-insulin dependent diabetes, osteoarthritis, hypothyroidism) may be enrolled based&#xD;
             on the clinical judgment of the Investigator.&#xD;
&#xD;
          2. For all cohorts except Cohort 5, subjects must be of Japanese ethnicity, defined as&#xD;
             having four ethnic Japanese grandparents. Subjects may not have lived outside of Japan&#xD;
             for more than 10 years. For Cohort 5, subjects must be of Caucasian race.&#xD;
&#xD;
          3. Must be between the ages of 18 and 75 years, inclusive, at the time of signing of the&#xD;
             Inform Consent Form (ICF).&#xD;
&#xD;
          4. Agrees to have any dietary or nutritional supplements reviewed by the Investigator and&#xD;
             potentially held during the study if advised by the Investigator. Standard&#xD;
             multivitamin and mineral supplementation will be permitted.&#xD;
&#xD;
          5. Agrees to comply with the contraception and reproduction restrictions of the study:&#xD;
&#xD;
               -  Men whose sexual partner is of childbearing potential and/or who are not&#xD;
                  monogamous must be using two acceptable methods of contraception, at least one of&#xD;
                  which must be a barrier method (e.g., spermicidal gel plus condom), for the&#xD;
                  entire duration of the study and for at least 1 month following study-drug&#xD;
                  administration; and men must refrain from attempting to father a child or&#xD;
                  donating sperm in the 1 month following the study-drug administration. Periodic&#xD;
                  abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and&#xD;
                  withdrawal are not acceptable methods of contraception.&#xD;
&#xD;
               -  Men who report surgical sterilization (e.g., bilateral vasectomy) must have had&#xD;
                  the procedure at least 6 months before study drug administration.&#xD;
&#xD;
               -  Surgical sterilization procedures should be supported with clinical documentation&#xD;
                  and noted in the Relevant Medical History/Current Medical Conditions section of&#xD;
                  the case report forms (CRFs).&#xD;
&#xD;
               -  Women of childbearing potential must be using two medically acceptable methods of&#xD;
                  contraception, at least one of which must be a barrier method (e.g., non-hormone&#xD;
                  containing intra-uterine device plus condom, spermicidal gel plus condom,&#xD;
                  diaphragm plus condom), from the time of Screening and for the duration of the&#xD;
                  study, through at least 1 month following study drug administration. Note: Oral&#xD;
                  and topical hormonal contraceptive use, as well as the use of hormone-containing&#xD;
                  intra-uterine devices, is not permitted due to their increased risk of&#xD;
                  thromboembolism. Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                  post- ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception; OR&#xD;
&#xD;
               -  Postmenopausal women must have had no regular menstrual bleeding for at least 1&#xD;
                  year before initial dosing and either be over the age of 60 years or have an&#xD;
                  elevated plasma follicle-stimulating hormone (FSH) level (i.e., &gt; 40&#xD;
                  milli-international units (mIU)/mL) at Screening;&#xD;
&#xD;
               -  Women who report surgical sterilization (i.e., hysterectomy, tubal ligation,&#xD;
                  and/or bilateral oophorectomy) must have had the procedure at least 6 months&#xD;
                  before study drug administration. Surgical sterilization procedures should be&#xD;
                  supported with clinical documentation and noted in the Relevant Medical&#xD;
                  History/Current Medical Conditions section of the CRF; AND All female subjects&#xD;
                  must have a documented negative pregnancy test result at Screening and on Study&#xD;
                  Day -1.&#xD;
&#xD;
          6. Systolic blood pressure &lt; 160 mmHg and diastolic blood pressure &lt; 90 mmHg at Screening&#xD;
             and Day -1.&#xD;
&#xD;
          7. The following laboratory values must be within the normal laboratory reference range&#xD;
             within 45 days of Day -1: Prothrombin Time (PT), Activated Partial Thromboplastin Time&#xD;
             (aPTT), and Activated Clotting Time (ACT); hemoglobin, hematocrit, and platelet count.&#xD;
&#xD;
          8. The following laboratory values must be equal to or below 2 times the upper limit of&#xD;
             normal (ULN) range within 45 days of Day -1: Aspartate aminotransferase (AST)/alanine&#xD;
             aminotransferase (ALT) and total bilirubin.&#xD;
&#xD;
          9. The Screening serum creatinine must be below 1.5 mg/dL within 45 days of Day -1.&#xD;
&#xD;
         10. Body mass index of less than 30 kg/m2, inclusive, and body weight between 50 kg and 80&#xD;
             kg, inclusive. In addition, subjects must be greater than 60 kg for Cohorts 3, 4, and&#xD;
             10.&#xD;
&#xD;
         11. Agrees to abstain from alcohol consumption for the duration of the domicile period,&#xD;
             and from the use of drugs of abuse for the duration of the study.&#xD;
&#xD;
         12. Able to read and give written informed consent and has signed a consent form approved&#xD;
             by the Investigator's Institutional Review Board (IRB) or Independent Ethics Committee&#xD;
             (IEC).&quot;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous use of andexanet or previous participation in the current study (even if the&#xD;
             subject received placebo).&#xD;
&#xD;
          2. History of abnormal bleeding, signs or symptoms of active bleeding, or risk factors&#xD;
             for bleeding.&#xD;
&#xD;
          3. Has a stool specimen that was positive for occult blood within 6 months of study&#xD;
             Screening or during the Screening Period.&#xD;
&#xD;
          4. Past or current medical history of thrombosis, any sign or symptom that suggests an&#xD;
             increased risk of a systemic thrombotic condition or thrombotic event, or recent&#xD;
             events that may increase risk of thrombosis.&#xD;
&#xD;
             a. For example, subjects with a known or suspected hypercoagulable state, history of&#xD;
             Venous Thromboembolism(VTE), Deep Venous Thrombosis (DVT), stroke, myocardial&#xD;
             infarction (MI), cancer (other than non-melanoma skin cancer), atrial fibrillation,&#xD;
             heart failure, cardiomyopathy, phlebitis, lower extremity edema, major surgery, or&#xD;
             trauma within 2 months of Study Day -1, airplane travel with a planned flight time for&#xD;
             any single flight segment â‰¥ 6 hours during the 4 weeks prior to Study Day -1, or&#xD;
             general immobility are excluded.&#xD;
&#xD;
          5. Absolute or relative contraindication to anticoagulation or treatment with apixaban,&#xD;
             rivaroxaban, and/or edoxaban.&#xD;
&#xD;
          6. Prior consumption of (by any route) one or more doses of aspirin (including baby&#xD;
             aspirin), salicylate or subsalicylate, other antiplatelet drugs (e.g., ticlopidine,&#xD;
             clopidogrel), non-steroidal anti-inflammatory drugs, fibrinolytic, or any&#xD;
             anticoagulant within 7 days prior to Day -1 or is anticipated to require such drugs&#xD;
             during the study.&#xD;
&#xD;
          7. Receipt of (by any route) hormonal contraception, post- menopausal hormone replacement&#xD;
             therapy (HRT) (including over-the-counter products), or testosterone during the 4&#xD;
             weeks prior to Study Day -1 or is anticipated to require such drugs during the study.&#xD;
&#xD;
          8. Family history of or risk factors for a hypercoagulable or thrombotic condition,&#xD;
             including one of the following:&#xD;
&#xD;
               1. Factor V Leiden carrier or homozygote.&#xD;
&#xD;
               2. Protein C, S, or ATIII activity below the normal range.&#xD;
&#xD;
          9. History of adult asthma or chronic obstructive pulmonary disease or current regular or&#xD;
             as needed use of inhaled medications.&#xD;
&#xD;
         10. Active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or HIV-1/2 infection.&#xD;
&#xD;
         11. Use of any drugs that are strong dual inhibitors or inducers of CYP3A4 (apixaban and&#xD;
             rivaroxaban cohorts only) and P-gp (all cohorts) within 7 days prior to Study Day -1&#xD;
             or anticipated need for such drugs during the study.&#xD;
&#xD;
         12. Participation in an investigational drug study within 45 days of Day -1 or Day -1 is&#xD;
             within 5 half-lives of the investigational compound.&#xD;
&#xD;
         13. Positive screen for drugs of abuse at Day -1 that is not explained by a prescription&#xD;
             medication that the subject is known to be taking.&#xD;
&#xD;
         14. A medical or surgical condition that may impair drug (anticoagulant or andexanet)&#xD;
             metabolism.&#xD;
&#xD;
         15. Allergy to any of the vehicle ingredients: Tris, arginine, sucrose, hydrochloric acid,&#xD;
             mannitol, and polysorbate 80.&#xD;
&#xD;
         16. Allergy to soy or soy products.&#xD;
&#xD;
         17. Current breastfeeding or a positive pregnancy test at Screening or Day -1.&#xD;
&#xD;
         18. Any condition that could interfere with, or for which the treatment might interfere&#xD;
             with, the conduct of the study or interpretation of the study results, or that would&#xD;
             in the opinion of the Investigator increase the risk of the subject's participation in&#xD;
             the study. This would include but is not limited to alcoholism, drug dependency or&#xD;
             abuse, psychiatric disease, epilepsy, or any unexplained blackouts.&#xD;
&#xD;
         19. The subject is not judged by the study staff to have adequate bilateral venous access.&#xD;
&#xD;
         20. Unwillingness to adhere to the activity requirements of the study.&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <results_first_submitted>July 2, 2020</results_first_submitted>
  <results_first_submitted_qc>July 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2020</results_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan: Statistical Analysis Plan Part 1</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03310021/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03310021/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Statistical Analysis Plan Part 2</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03310021/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy Subjects</recruitment_details>
      <pre_assignment_details>One subject in cohort 10 (Edoxaban/Placebo) discontinued due to protocol deviation (mis-enrolled, inclusion criteria #10 not met(weight&gt;80kg). This subject (100003) is not summarized in tables because he/she did not receive any andexanet/Placebo. The safety population (N=107) is defined as having received study drug andexanet/placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 Apixaban 5 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+ 8 mg/min 120 minute infusion (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 Rivaroxaban 15 mg BID/Placebo</title>
          <description>Placebo 800 mg bolus+ 8 mg/min 120 minute infusion placebo (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="P5">
          <title>Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="P6">
          <title>Cohort 3 Edooxaban 60 mg QD/Placebo</title>
          <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="P7">
          <title>Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="P8">
          <title>Cohort 4 Edooxaban 60 mg QD/Placebo</title>
          <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="P9">
          <title>Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet</title>
          <description>400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Caucasian Subjects</description>
        </group>
        <group group_id="P10">
          <title>Cohort 5 Apixaban 5 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Caucasian Subjects</description>
        </group>
        <group group_id="P11">
          <title>Cohort 6 Apixaban 10 mg BID/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="P12">
          <title>Cohort 6 Apixaban 10 mg BID/Placebo</title>
          <description>Placebo 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="P13">
          <title>Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="P14">
          <title>Cohort 7 Edoxaban 30 mg QD/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="P15">
          <title>Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="P16">
          <title>Cohort 8 Apixaban 10 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="P17">
          <title>Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="P18">
          <title>Cohort 9 Rivaroxaban 15 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="P19">
          <title>Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="P20">
          <title>Cohort 10 Edoxaban 60 mg QD/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="10"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="10"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis population will include all enrolled subjects who received any amount of study drug (andexanet or placebo) treatment.&#xD;
All subjects in the safety population will be associated with the treatment actually received.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1 Apixaban 5 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+ 8 mg/min 120 minute infusion (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2 Rivaroxaban 15 mg BID/Placebo</title>
          <description>Placebo 800 mg bolus+ 8 mg/min 120 minute infusion placebo (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="B5">
          <title>Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="B6">
          <title>Cohort 3 Edooxaban 60 mg QD/Placebo</title>
          <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="B7">
          <title>Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="B8">
          <title>Cohort 4 Edooxaban 60 mg QD/Placebo</title>
          <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="B9">
          <title>Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet</title>
          <description>400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Caucasian Subjects</description>
        </group>
        <group group_id="B10">
          <title>Cohort 5 Apixaban 5 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Caucasian Subjects</description>
        </group>
        <group group_id="B11">
          <title>Cohort 6 Apixaban 10 mg BID/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="B12">
          <title>Cohort 6 Apixaban 10 mg BID/Placebo</title>
          <description>Placebo 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="B13">
          <title>Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="B14">
          <title>Cohort 7 Edoxaban 30 mg QD/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="B15">
          <title>Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="B16">
          <title>Cohort 8 Apixaban 10 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="B17">
          <title>Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="B18">
          <title>Cohort 9 Rivaroxaban 15 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="B19">
          <title>Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="B20">
          <title>Cohort 10 Edoxaban 60 mg QD/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="B21">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="3"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="3"/>
            <count group_id="B13" value="8"/>
            <count group_id="B14" value="4"/>
            <count group_id="B15" value="6"/>
            <count group_id="B16" value="3"/>
            <count group_id="B17" value="10"/>
            <count group_id="B18" value="5"/>
            <count group_id="B19" value="8"/>
            <count group_id="B20" value="3"/>
            <count group_id="B21" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.00" spread="8.99"/>
                    <measurement group_id="B2" value="52.00" spread="6.56"/>
                    <measurement group_id="B3" value="46.83" spread="17.50"/>
                    <measurement group_id="B4" value="55.33" spread="12.22"/>
                    <measurement group_id="B5" value="42.38" spread="10.45"/>
                    <measurement group_id="B6" value="36.75" spread="9.32"/>
                    <measurement group_id="B7" value="33.13" spread="9.26"/>
                    <measurement group_id="B8" value="33.00" spread="7.30"/>
                    <measurement group_id="B9" value="35.00" spread="14.53"/>
                    <measurement group_id="B10" value="30.33" spread="2.08"/>
                    <measurement group_id="B11" value="44.17" spread="11.02"/>
                    <measurement group_id="B12" value="42.33" spread="12.74"/>
                    <measurement group_id="B13" value="38.13" spread="11.04"/>
                    <measurement group_id="B14" value="47.75" spread="8.96"/>
                    <measurement group_id="B15" value="42.17" spread="7.70"/>
                    <measurement group_id="B16" value="46.33" spread="12.42"/>
                    <measurement group_id="B17" value="49.70" spread="12.88"/>
                    <measurement group_id="B18" value="33.60" spread="5.13"/>
                    <measurement group_id="B19" value="30.13" spread="9.91"/>
                    <measurement group_id="B20" value="39.00" spread="6.24"/>
                    <measurement group_id="B21" value="40.69" spread="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.50" lower_limit="32.0" upper_limit="55.0"/>
                    <measurement group_id="B2" value="51.00" lower_limit="46.0" upper_limit="59.0"/>
                    <measurement group_id="B3" value="47.50" lower_limit="24.0" upper_limit="67.0"/>
                    <measurement group_id="B4" value="58.00" lower_limit="42.0" upper_limit="66.0"/>
                    <measurement group_id="B5" value="45.00" lower_limit="29.0" upper_limit="56.0"/>
                    <measurement group_id="B6" value="35.50" lower_limit="27.0" upper_limit="49.0"/>
                    <measurement group_id="B7" value="33.0" lower_limit="21.0" upper_limit="50.0"/>
                    <measurement group_id="B8" value="31.50" lower_limit="25.0" upper_limit="41.0"/>
                    <measurement group_id="B9" value="31.50" lower_limit="21.0" upper_limit="60.0"/>
                    <measurement group_id="B10" value="31.00" lower_limit="28.0" upper_limit="32.0"/>
                    <measurement group_id="B11" value="46.50" lower_limit="26.0" upper_limit="55.0"/>
                    <measurement group_id="B12" value="36.00" lower_limit="34.0" upper_limit="57.0"/>
                    <measurement group_id="B13" value="34.50" lower_limit="23.0" upper_limit="59.0"/>
                    <measurement group_id="B14" value="47.00" lower_limit="38.0" upper_limit="59.0"/>
                    <measurement group_id="B15" value="41.00" lower_limit="33.0" upper_limit="53.0"/>
                    <measurement group_id="B16" value="53.00" lower_limit="32.0" upper_limit="54.0"/>
                    <measurement group_id="B17" value="51.00" lower_limit="28.0" upper_limit="69.0"/>
                    <measurement group_id="B18" value="35.00" lower_limit="26.0" upper_limit="40.0"/>
                    <measurement group_id="B19" value="28.50" lower_limit="20.0" upper_limit="48.0"/>
                    <measurement group_id="B20" value="41.00" lower_limit="32.0" upper_limit="44.0"/>
                    <measurement group_id="B21" value="38.00" lower_limit="20.0" upper_limit="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="4"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="1"/>
                    <measurement group_id="B21" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="4"/>
                    <measurement group_id="B19" value="6"/>
                    <measurement group_id="B20" value="2"/>
                    <measurement group_id="B21" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="10"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="8"/>
                    <measurement group_id="B20" value="3"/>
                    <measurement group_id="B21" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir.</title>
        <description>The primary efficacy endpoint is the percent change in the anti-FXa activity from baseline to the end of infusion (EOI) nadir.</description>
        <time_frame>Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours</time_frame>
        <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+ 8 mg/min 120 minute infusion (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+ 8 mg/min 120 minute infusion placebo (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O9">
            <title>Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O10">
            <title>Cohort 5 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O11">
            <title>Cohort 6 Apixaban 10 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O12">
            <title>Cohort 6 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O13">
            <title>Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O14">
            <title>Cohort 7 Edoxaban 30 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O15">
            <title>Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O16">
            <title>Cohort 8 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O17">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O18">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O19">
            <title>Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O20">
            <title>Cohort 10 Edoxaban 60 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir.</title>
          <description>The primary efficacy endpoint is the percent change in the anti-FXa activity from baseline to the end of infusion (EOI) nadir.</description>
          <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="4"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="10"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-94.50" lower_limit="-96.00" upper_limit="-90.00"/>
                    <measurement group_id="O2" value="-29.00" lower_limit="-32.00" upper_limit="-18.00"/>
                    <measurement group_id="O3" value="-98.00" lower_limit="-99.00" upper_limit="-97.00"/>
                    <measurement group_id="O4" value="-37.00" lower_limit="-53.00" upper_limit="-34.00"/>
                    <measurement group_id="O5" value="-81.00" lower_limit="-89.00" upper_limit="-51.00"/>
                    <measurement group_id="O6" value="-47.50" lower_limit="-62.00" upper_limit="-34.00"/>
                    <measurement group_id="O7" value="-75.50" lower_limit="-82.00" upper_limit="-45.00"/>
                    <measurement group_id="O8" value="-37.00" lower_limit="-46.00" upper_limit="-16.00"/>
                    <measurement group_id="O9" value="-93.00" lower_limit="-94.00" upper_limit="-91.00"/>
                    <measurement group_id="O10" value="-34.00" lower_limit="-53.00" upper_limit="-24.00"/>
                    <measurement group_id="O11" value="-97.00" lower_limit="-98.00" upper_limit="-96.00"/>
                    <measurement group_id="O12" value="-31.00" lower_limit="-35.00" upper_limit="-30.00"/>
                    <measurement group_id="O13" value="-52.50" lower_limit="-69.00" upper_limit="-34.00"/>
                    <measurement group_id="O14" value="-37.00" lower_limit="-67.00" upper_limit="-17.00"/>
                    <measurement group_id="O15" value="-92.00" lower_limit="-95.00" upper_limit="-90.00"/>
                    <measurement group_id="O16" value="-24.00" lower_limit="-31.00" upper_limit="-21.00"/>
                    <measurement group_id="O17" value="-93.50" lower_limit="-98.00" upper_limit="-89.00"/>
                    <measurement group_id="O18" value="-37.00" lower_limit="-56.00" upper_limit="-29.00"/>
                    <measurement group_id="O19" value="-63.50" lower_limit="-80.00" upper_limit="-57.00"/>
                    <measurement group_id="O20" value="-27.00" lower_limit="-34.00" upper_limit="-25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0275</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-65.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.00</ci_lower_limit>
            <ci_upper_limit>-58.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.00</ci_lower_limit>
            <ci_upper_limit>-44.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0136</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-32.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.00</ci_lower_limit>
            <ci_upper_limit>-9.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0136</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-36.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.00</ci_lower_limit>
            <ci_upper_limit>-9.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.00</ci_lower_limit>
            <ci_upper_limit>-38.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0119</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.00</ci_lower_limit>
            <ci_upper_limit>-61.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2667</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-15.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.00</ci_lower_limit>
            <ci_upper_limit>17.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O15</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0238</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.00</ci_lower_limit>
            <ci_upper_limit>-59.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O18</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-56.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.00</ci_lower_limit>
            <ci_upper_limit>-39.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O19</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0121</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.00</ci_lower_limit>
            <ci_upper_limit>-24.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Anti-Fxa Activity From Baseline to the End of Bolus (EOB) Nadir.</title>
        <description>The percent change from baseline in anti-FXa activity at its end of bolus (EOB) nadir.</description>
        <time_frame>Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours</time_frame>
        <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+ 8 mg/min 120 minute infusion (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+ 8 mg/min 120 minute infusion placebo (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O9">
            <title>Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O10">
            <title>Cohort 5 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O11">
            <title>Cohort 6 Apixaban 10 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O12">
            <title>Cohort 6 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O13">
            <title>Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O14">
            <title>Cohort 7 Edoxaban 30 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O15">
            <title>Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O16">
            <title>Cohort 8 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O17">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O18">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O19">
            <title>Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O20">
            <title>Cohort 10 Edoxaban 60 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Anti-Fxa Activity From Baseline to the End of Bolus (EOB) Nadir.</title>
          <description>The percent change from baseline in anti-FXa activity at its end of bolus (EOB) nadir.</description>
          <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="4"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="10"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-94.50" lower_limit="-95.00" upper_limit="-92.00"/>
                    <measurement group_id="O2" value="-14.00" lower_limit="-15.00" upper_limit="-12.00"/>
                    <measurement group_id="O3" value="-97.50" lower_limit="-98.00" upper_limit="-96.00"/>
                    <measurement group_id="O4" value="-18.00" lower_limit="-29.00" upper_limit="-1.00"/>
                    <measurement group_id="O5" value="-65.50" lower_limit="-87.00" upper_limit="-8.00"/>
                    <measurement group_id="O6" value="-16.00" lower_limit="-46.00" upper_limit="-13.00"/>
                    <measurement group_id="O7" value="-22.50" lower_limit="-78.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="-15.00" lower_limit="-19.00" upper_limit="7.00"/>
                    <measurement group_id="O9" value="-94.00" lower_limit="-94.00" upper_limit="-92.00"/>
                    <measurement group_id="O10" value="-10.00" lower_limit="-21.00" upper_limit="-7.00"/>
                    <measurement group_id="O11" value="-96.00" lower_limit="-97.00" upper_limit="-95.00"/>
                    <measurement group_id="O12" value="-18.00" lower_limit="-21.00" upper_limit="-14.00"/>
                    <measurement group_id="O13" value="-58.00" lower_limit="-78.00" upper_limit="-1.00"/>
                    <measurement group_id="O14" value="-8.00" lower_limit="-13.00" upper_limit="-1.00"/>
                    <measurement group_id="O15" value="-94.50" lower_limit="-96.00" upper_limit="-93.00"/>
                    <measurement group_id="O16" value="-5.00" lower_limit="-16.00" upper_limit="-3.00"/>
                    <measurement group_id="O17" value="-95.00" lower_limit="-98.00" upper_limit="-93.00"/>
                    <measurement group_id="O18" value="-11.00" lower_limit="-28.00" upper_limit="-9.00"/>
                    <measurement group_id="O19" value="-73.00" lower_limit="-80.00" upper_limit="-61.00"/>
                    <measurement group_id="O20" value="-4.00" lower_limit="-12.00" upper_limit="-4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0256</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.00</ci_lower_limit>
            <ci_upper_limit>-77.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-79.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-97.00</ci_lower_limit>
            <ci_upper_limit>-67.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.00</ci_lower_limit>
            <ci_upper_limit>5.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1066</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-10.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.00</ci_lower_limit>
            <ci_upper_limit>10.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0219</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-87.00</ci_lower_limit>
            <ci_upper_limit>-71.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0262</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.00</ci_lower_limit>
            <ci_upper_limit>-74.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0412</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.00</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O15</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0269</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-89.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-93.00</ci_lower_limit>
            <ci_upper_limit>-77.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O18</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.00</ci_lower_limit>
            <ci_upper_limit>-69.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O19</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0181</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.00</ci_lower_limit>
            <ci_upper_limit>-57.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Bolus (EOB) Nadir.</title>
        <description>The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOB nadir.</description>
        <time_frame>Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours</time_frame>
        <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+ 8 mg/min 120 minute infusion (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+ 8 mg/min 120 minute infusion placebo (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O9">
            <title>Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O10">
            <title>Cohort 5 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O11">
            <title>Cohort 6 Apixaban 10 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O12">
            <title>Cohort 6 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O13">
            <title>Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O14">
            <title>Cohort 7 Edoxaban 30 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O15">
            <title>Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O16">
            <title>Cohort 8 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O17">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O18">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O19">
            <title>Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O20">
            <title>Cohort 10 Edoxaban 60 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Bolus (EOB) Nadir.</title>
          <description>The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOB nadir.</description>
          <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="4"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="9"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-93.00" lower_limit="-94.70" upper_limit="-90.38"/>
                    <measurement group_id="O2" value="-11.94" lower_limit="-18.42" upper_limit="-1.71"/>
                    <measurement group_id="O3" value="-97.72" lower_limit="-97.97" upper_limit="-95.70"/>
                    <measurement group_id="O4" value="-28.57" lower_limit="-47.06" upper_limit="-1.06"/>
                    <measurement group_id="O5" value="-78.20" lower_limit="-86.17" upper_limit="-59.17"/>
                    <measurement group_id="O6" value="-17.60" lower_limit="-27.95" upper_limit="-10.15"/>
                    <measurement group_id="O7" value="-56.05" lower_limit="-77.92" upper_limit="-40.69"/>
                    <measurement group_id="O8" value="-2.49" lower_limit="-28.57" upper_limit="12.48"/>
                    <measurement group_id="O9" value="-94.45" lower_limit="-96.56" upper_limit="-93.04"/>
                    <measurement group_id="O10" value="5.80" lower_limit="-8.56" upper_limit="36.52"/>
                    <measurement group_id="O11" value="-93.57" lower_limit="-97.30" upper_limit="-90.08"/>
                    <measurement group_id="O12" value="-12.94" lower_limit="-24.34" upper_limit="-10.94"/>
                    <measurement group_id="O13" value="-70.88" lower_limit="-87.12" upper_limit="-44.80"/>
                    <measurement group_id="O14" value="-5.48" lower_limit="-12.67" upper_limit="18.07"/>
                    <measurement group_id="O15" value="-91.61" lower_limit="-95.51" upper_limit="-89.76"/>
                    <measurement group_id="O16" value="-0.32" lower_limit="-28.93" upper_limit="33.37"/>
                    <measurement group_id="O17" value="-95.51" lower_limit="-97.09" upper_limit="-93.43"/>
                    <measurement group_id="O18" value="-14.02" lower_limit="-30.10" upper_limit="-4.10"/>
                    <measurement group_id="O19" value="-75.80" lower_limit="-85.51" upper_limit="-70.44"/>
                    <measurement group_id="O20" value="-17.91" lower_limit="-26.80" upper_limit="26.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-81.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-92.99</ci_lower_limit>
            <ci_upper_limit>-71.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-69.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-96.91</ci_lower_limit>
            <ci_upper_limit>-48.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-57.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.07</ci_lower_limit>
            <ci_upper_limit>-40.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-54.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-80.42</ci_lower_limit>
            <ci_upper_limit>-25.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-100.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-133.08</ci_lower_limit>
            <ci_upper_limit>-84.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-79.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.36</ci_lower_limit>
            <ci_upper_limit>-65.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-65.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-89.54</ci_lower_limit>
            <ci_upper_limit>-39.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O15</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-91.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-128.88</ci_lower_limit>
            <ci_upper_limit>-60.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O18</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-81.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-91.05</ci_lower_limit>
            <ci_upper_limit>-65.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O19</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0189</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-58.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-110.86</ci_lower_limit>
            <ci_upper_limit>-46.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Infusion (EOI) Nadir.</title>
        <description>The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOI nadir.</description>
        <time_frame>Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours</time_frame>
        <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+ 8 mg/min 120 minute infusion (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+ 8 mg/min 120 minute infusion placebo (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O9">
            <title>Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O10">
            <title>Cohort 5 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O11">
            <title>Cohort 6 Apixaban 10 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O12">
            <title>Cohort 6 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O13">
            <title>Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O14">
            <title>Cohort 7 Edoxaban 30 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O15">
            <title>Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O16">
            <title>Cohort 8 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O17">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O18">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O19">
            <title>Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O20">
            <title>Cohort 10 Edoxaban 60 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Infusion (EOI) Nadir.</title>
          <description>The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOI nadir.</description>
          <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="4"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="10"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.940" lower_limit="-94.610" upper_limit="-90.400"/>
                    <measurement group_id="O2" value="-33.550" lower_limit="-37.780" upper_limit="-28.130"/>
                    <measurement group_id="O3" value="-98.650" lower_limit="-99.060" upper_limit="-97.610"/>
                    <measurement group_id="O4" value="-39.390" lower_limit="-70.670" upper_limit="-28.720"/>
                    <measurement group_id="O5" value="-85.005" lower_limit="-93.140" upper_limit="-68.740"/>
                    <measurement group_id="O6" value="-48.710" lower_limit="-49.790" upper_limit="-38.980"/>
                    <measurement group_id="O7" value="-81.040" lower_limit="-89.300" upper_limit="-67.660"/>
                    <measurement group_id="O8" value="-42.755" lower_limit="-53.330" upper_limit="-25.890"/>
                    <measurement group_id="O9" value="-93.495" lower_limit="-96.180" upper_limit="-91.240"/>
                    <measurement group_id="O10" value="-31.830" lower_limit="-47.460" upper_limit="-20.360"/>
                    <measurement group_id="O11" value="-96.65" lower_limit="-97.62" upper_limit="-94.80"/>
                    <measurement group_id="O12" value="-29.02" lower_limit="-32.81" upper_limit="-20.22"/>
                    <measurement group_id="O13" value="-62.72" lower_limit="-76.52" upper_limit="-55.03"/>
                    <measurement group_id="O14" value="-24.34" lower_limit="-46.86" upper_limit="-11.07"/>
                    <measurement group_id="O15" value="-90.63" lower_limit="-91.57" upper_limit="-86.02"/>
                    <measurement group_id="O16" value="-31.45" lower_limit="-37.88" upper_limit="9.45"/>
                    <measurement group_id="O17" value="-94.89" lower_limit="-97.44" upper_limit="-85.09"/>
                    <measurement group_id="O18" value="-37.82" lower_limit="-54.92" upper_limit="-36.30"/>
                    <measurement group_id="O19" value="-67.10" lower_limit="-81.33" upper_limit="-49.62"/>
                    <measurement group_id="O20" value="-34.25" lower_limit="-36.17" upper_limit="-15.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-59.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.48</ci_lower_limit>
            <ci_upper_limit>-52.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-59.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.34</ci_lower_limit>
            <ci_upper_limit>-26.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-36.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.14</ci_lower_limit>
            <ci_upper_limit>-29.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-36.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.81</ci_lower_limit>
            <ci_upper_limit>-20.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-61.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-75.82</ci_lower_limit>
            <ci_upper_limit>-43.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-67.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.40</ci_lower_limit>
            <ci_upper_limit>-61.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-40.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.77</ci_lower_limit>
            <ci_upper_limit>-11.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O15</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-59.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-101.02</ci_lower_limit>
            <ci_upper_limit>-48.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O18</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-54.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.14</ci_lower_limit>
            <ci_upper_limit>-41.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O19</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0189</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>-38.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.78</ci_lower_limit>
            <ci_upper_limit>-15.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thrombin Generation From Baseline to the End of Bolus (EOB) Nadir.</title>
        <description>The change in thrombin generation from baseline to its EOB peak.</description>
        <time_frame>Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours</time_frame>
        <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+ 8 mg/min 120 minute infusion (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+ 8 mg/min 120 minute infusion placebo (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O9">
            <title>Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O10">
            <title>Cohort 5 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O11">
            <title>Cohort 6 Apixaban 10 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O12">
            <title>Cohort 6 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O13">
            <title>Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O14">
            <title>Cohort 7 Edoxaban 30 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O15">
            <title>Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O16">
            <title>Cohort 8 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O17">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O18">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O19">
            <title>Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O20">
            <title>Cohort 10 Edoxaban 60 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombin Generation From Baseline to the End of Bolus (EOB) Nadir.</title>
          <description>The change in thrombin generation from baseline to its EOB peak.</description>
          <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
          <units>nM.min</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="4"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="10"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1145.03" lower_limit="708.92" upper_limit="1538.44"/>
                    <measurement group_id="O2" value="179.94" lower_limit="161.09" upper_limit="234.44"/>
                    <measurement group_id="O3" value="1337.28" lower_limit="1155.95" upper_limit="1632.28"/>
                    <measurement group_id="O4" value="209.99" lower_limit="57.26" upper_limit="386.49"/>
                    <measurement group_id="O5" value="758.92" lower_limit="560.66" upper_limit="1494.51"/>
                    <measurement group_id="O6" value="215.71" lower_limit="-15.75" upper_limit="319.23"/>
                    <measurement group_id="O7" value="815.07" lower_limit="603.90" upper_limit="949.73"/>
                    <measurement group_id="O8" value="48.59" lower_limit="22.87" upper_limit="165.84"/>
                    <measurement group_id="O9" value="1244.30" lower_limit="1106.36" upper_limit="1714.52"/>
                    <measurement group_id="O10" value="103.13" lower_limit="-22.26" upper_limit="142.33"/>
                    <measurement group_id="O11" value="1177.47" lower_limit="1081.47" upper_limit="1564.10"/>
                    <measurement group_id="O12" value="0.16" lower_limit="-106.20" upper_limit="92.65"/>
                    <measurement group_id="O13" value="781.42" lower_limit="381.40" upper_limit="918.54"/>
                    <measurement group_id="O14" value="67.97" lower_limit="-319.74" upper_limit="157.51"/>
                    <measurement group_id="O15" value="1184.62" lower_limit="1038.43" upper_limit="1394.74"/>
                    <measurement group_id="O16" value="2.69" lower_limit="-76.71" upper_limit="36.71"/>
                    <measurement group_id="O17" value="1306.23" lower_limit="846.48" upper_limit="1442.27"/>
                    <measurement group_id="O18" value="117.50" lower_limit="44.14" upper_limit="163.39"/>
                    <measurement group_id="O19" value="902.17" lower_limit="582.77" upper_limit="1405.55"/>
                    <measurement group_id="O20" value="-92.82" lower_limit="-245.48" upper_limit="198.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>965.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>474.48</ci_lower_limit>
            <ci_upper_limit>1377.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>1127.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>769.46</ci_lower_limit>
            <ci_upper_limit>1575.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>574.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>307.65</ci_lower_limit>
            <ci_upper_limit>1175.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>715.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>535.38</ci_lower_limit>
            <ci_upper_limit>836.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>1141.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>964.03</ci_lower_limit>
            <ci_upper_limit>1736.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>1198.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>988.82</ci_lower_limit>
            <ci_upper_limit>1670.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>721.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>585.92</ci_lower_limit>
            <ci_upper_limit>1108.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O15</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>1204.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1001.72</ci_lower_limit>
            <ci_upper_limit>1471.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O18</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>1180.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>857.21</ci_lower_limit>
            <ci_upper_limit>1296.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O19</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0189</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>976.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>585.99</ci_lower_limit>
            <ci_upper_limit>1498.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thrombin Generation From Baseline to the End of Infusion (EOI) Nadir.</title>
        <description>The change in thrombin generation from baseline to its EOI peak.</description>
        <time_frame>Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours</time_frame>
        <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+ 8 mg/min 120 minute infusion (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+ 8 mg/min 120 minute infusion placebo (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Edooxaban 60 mg QD/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O9">
            <title>Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet</title>
            <description>400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O10">
            <title>Cohort 5 Apixaban 5 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Caucasian Subjects</description>
          </group>
          <group group_id="O11">
            <title>Cohort 6 Apixaban 10 mg BID/High Dose Andexanet</title>
            <description>Andexanet 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O12">
            <title>Cohort 6 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O13">
            <title>Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O14">
            <title>Cohort 7 Edoxaban 30 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O15">
            <title>Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O16">
            <title>Cohort 8 Apixaban 10 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
          </group>
          <group group_id="O17">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O18">
            <title>Cohort 9 Rivaroxaban 15 mg BID/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
          </group>
          <group group_id="O19">
            <title>Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet</title>
            <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
          <group group_id="O20">
            <title>Cohort 10 Edoxaban 60 mg QD/Placebo</title>
            <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombin Generation From Baseline to the End of Infusion (EOI) Nadir.</title>
          <description>The change in thrombin generation from baseline to its EOI peak.</description>
          <population>Efficacy Population: all randomized subjects who received andexanet or placebo during the double-blind treatment period and had at least one evaluable post-baseline efficacy assessment as well as the required baseline sample assessment.</population>
          <units>nM.min</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="4"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="3"/>
                <count group_id="O17" value="10"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000.630" lower_limit="695.120" upper_limit="1519.850"/>
                    <measurement group_id="O2" value="171.220" lower_limit="157.740" upper_limit="189.720"/>
                    <measurement group_id="O3" value="1329.580" lower_limit="1161.360" upper_limit="1679.680"/>
                    <measurement group_id="O4" value="207.590" lower_limit="126.910" upper_limit="287.490"/>
                    <measurement group_id="O5" value="804.405" lower_limit="692.880" upper_limit="1560.300"/>
                    <measurement group_id="O6" value="347.535" lower_limit="107.360" upper_limit="482.840"/>
                    <measurement group_id="O7" value="910.935" lower_limit="775.950" upper_limit="1108.160"/>
                    <measurement group_id="O8" value="236.610" lower_limit="126.010" upper_limit="295.710"/>
                    <measurement group_id="O9" value="1130.575" lower_limit="1022.120" upper_limit="1460.710"/>
                    <measurement group_id="O10" value="118.130" lower_limit="108.660" upper_limit="163.040"/>
                    <measurement group_id="O11" value="1119.41" lower_limit="969.95" upper_limit="1567.02"/>
                    <measurement group_id="O12" value="108.67" lower_limit="-67.28" upper_limit="150.99"/>
                    <measurement group_id="O13" value="833.46" lower_limit="571.27" upper_limit="939.46"/>
                    <measurement group_id="O14" value="175.72" lower_limit="-290.06" upper_limit="336.63"/>
                    <measurement group_id="O15" value="1058.09" lower_limit="809.14" upper_limit="1335.39"/>
                    <measurement group_id="O16" value="138.14" lower_limit="119.11" upper_limit="145.40"/>
                    <measurement group_id="O17" value="1173.38" lower_limit="773.75" upper_limit="1399.21"/>
                    <measurement group_id="O18" value="293.15" lower_limit="142.08" upper_limit="324.41"/>
                    <measurement group_id="O19" value="793.44" lower_limit="564.56" upper_limit="1339.52"/>
                    <measurement group_id="O20" value="-72.69" lower_limit="-302.36" upper_limit="52.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>826.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>505.40</ci_lower_limit>
            <ci_upper_limit>1362.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>1125.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>873.87</ci_lower_limit>
            <ci_upper_limit>1552.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>538.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>291.20</ci_lower_limit>
            <ci_upper_limit>1077.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>687.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>500.92</ci_lower_limit>
            <ci_upper_limit>902.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>1012.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>859.08</ci_lower_limit>
            <ci_upper_limit>1352.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>1057.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>818.96</ci_lower_limit>
            <ci_upper_limit>1634.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>630.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>421.78</ci_lower_limit>
            <ci_upper_limit>1124.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O15</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>925.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>663.74</ci_lower_limit>
            <ci_upper_limit>1216.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O17</group_id>
              <group_id>O18</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>871.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>631.67</ci_lower_limit>
            <ci_upper_limit>1051.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O19</group_id>
              <group_id>O20</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0189</p_value>
            <method>2-sided Wilcoxon Rank Sum</method>
            <param_type>Hodges lehman Location shift</param_type>
            <param_value>874.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>637.25</ci_lower_limit>
            <ci_upper_limit>1412.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study day 1 to 39</time_frame>
      <desc>Treatment emergent AEs occurring between informed consent and the Termination Visit will be recorded on the e-CRFs. All AEs should be monitored until they are resolved, reach a level of stability and are not expected to improve further, or are clearly determined to be due to a subject's stable or chronic condition or intercurrent illness. Any AE that begins after completion of the study and that the Investigator considers to be related to study medication, must be reported to Portola.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 Apixaban 5 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+ 8 mg/min 120 minute infusion (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 Rivaroxaban 15 mg BID/Placebo</title>
          <description>Placebo 800 mg bolus+ 8 mg/min 120 minute infusion placebo (dosing at 4 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="E5">
          <title>Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="E6">
          <title>Cohort 3 Edooxaban 60 mg QD/Placebo</title>
          <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 3 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="E7">
          <title>Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="E8">
          <title>Cohort 4 Edooxaban 60 mg QD/Placebo</title>
          <description>Placebo 800 mg bolus+8 mg/min 120 minutes infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="E9">
          <title>Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet</title>
          <description>400 mg bolus+4 mg/min 120 minute Andexanet infusion (dosing at 3 hours post-apixaban); Caucasian Subjects</description>
        </group>
        <group group_id="E10">
          <title>Cohort 5 Apixaban 5 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (placebo dosing at 3 hours post-apixaban); Caucasian Subjects</description>
        </group>
        <group group_id="E11">
          <title>Cohort 6 Apixaban 10 mg BID/High Dose Andexanet</title>
          <description>Andexanet 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="E12">
          <title>Cohort 6 Apixaban 10 mg BID/Placebo</title>
          <description>Placebo 800 mg bolus+8 mg/min 120 minute infusion (dosing at 3 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="E13">
          <title>Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="E14">
          <title>Cohort 7 Edoxaban 30 mg QD/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 90 minutes post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="E15">
          <title>Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="E16">
          <title>Cohort 8 Apixaban 10 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-apixaban); Japanese Subjects</description>
        </group>
        <group group_id="E17">
          <title>Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="E18">
          <title>Cohort 9 Rivaroxaban 15 mg BID/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-rivaroxaban); Japanese Subjects</description>
        </group>
        <group group_id="E19">
          <title>Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet</title>
          <description>Andexanet 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
        </group>
        <group group_id="E20">
          <title>Cohort 10 Edoxaban 60 mg QD/Placebo</title>
          <description>Placebo 400 mg bolus+4 mg/min 120 minute infusion (dosing at 8 hours post-edoxaban); Japanese Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Aphthous Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infusion Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash Pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Development</name_or_title>
      <organization>Portola Pharmaceuticals</organization>
      <phone>6502767153</phone>
      <email>ClinicalTrials@Portola.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

